Renalyse, a CataloniaBio & HealthTech member, has concluded an investment round led by the Mind the Gap program of the Botín Foundation, with participation from GENESIS Ventures and the Eurostars program. In this manner, Renalyse has secured 1 M€ that will be allocated towards the industrialization and certification of its Chronic Kidney Disease diagnostic and monitoring device.

This investment round is spearheaded by Mind the Gap, the Botín Foundation's program aimed at promoting biotechnological entrepreneurship. It operates through a co-investment vehicle with the participation of private investors alongside the Foundation. Mind the Gap has committed an investment of €500,000 in Renalyse. Íñigo Sáenz de Miera, the General Director of the Botín Foundation, emphasizes, “This investment in Renalyse reinforces the Botín Foundation's commitment to supporting Spanish entrepreneurs developing biomedical innovation with a high socio-health impact.”

GENESIS Ventures, managed by the consulting firm GENESIS Biomed, also a CataloniaBio & HealthTech member, is also a participant in this operation. Established in 2017 with a total of €2.5 million, GENESIS Ventures aims to invest tickets ranging from €25,000 to €100,000 in early-stage biomedical projects. It has invested a total of €100,000 in Renalyse. According to Josep Lluís Falcó, the administrator of GENESIS Ventures and co-founder and CEO of GENESIS Biomed, “Renalyse represents a significant investment for our portfolio of companies. It is developing a diagnostic device that will revolutionize the clinical management of patients with chronic kidney failure. Furthermore, the involvement of the Botín Foundation in this project, along with institutions already present such as the Hospital Clínic or BStartup Health, confirms that Renalyse is a winning investment. We are excited to become part of the company's Board of Directors.”

The company was founded in 2017 with the aim of developing a medical device to enhance kidney disease treatments. The funding acquired through this operation will enable Renalyse to certify its in vitro diagnostic product and enter the market by 2026. This device, also named Renalyse, will remotely measure three key parameters for patients with chronic kidney disease, a population exceeding 90 million in the European Union.

This project, currently in the pre-industrialization phase, will introduce an assistance platform for personal use. It can be utilized by both patients at home and doctors in primary care consultations. Currently, the monitoring of these parameters is conducted through blood tests in clinical laboratories or with devices in hospital emergency areas used by specialists. Renalyse's value proposition is a more economical device that provides immediate results, allowing patients to monitor their disease from home without needing to be experts.